We previously demonstrated that, in chemoresistant colon cancer, breast cancer, and malignant pleural mesothelioma, RAS/ERK1/2 inhibition reduces the phosphorylation and the stability of HIF1α, a transcriptional inducer of Pgp, even in normoxia. This evidence concerns the gene HIF1A and breast carcinoma.